A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
出版年份 2020 全文链接
标题
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
作者
关键词
-
出版物
Blood Advances
Volume 4, Issue 23, Pages 5988-5999
出版商
American Society of Hematology
发表日期
2020-12-09
DOI
10.1182/bloodadvances.2020002827
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
- (2020) Dilan A. Patel et al. BONE MARROW TRANSPLANTATION
- Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients
- (2019) Thierry Facon et al. BLOOD
- Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study
- (2019) Theresa E. Hahn et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis
- (2019) Hanqing Li et al. ANNALS OF HEMATOLOGY
- Imaging and Bone Marrow Assessments Improve Minimal Residual Disease Prediction in Multiple Myeloma
- (2019) Rafael Alonso et al. AMERICAN JOURNAL OF HEMATOLOGY
- Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia
- (2019) Nizar Bahlis et al. BLOOD
- Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)
- (2019) Takeshi Yoroidaka et al. BLOOD
- Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
- (2019) Bruno Paiva et al. JOURNAL OF CLINICAL ONCOLOGY
- BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
- (2018) Sarah A. Holstein et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy
- (2018) C. Amos Clark et al. BONE MARROW TRANSPLANTATION
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Flow Cytometry Identified “Minimal Residual Disease” (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma
- (2018) Jingli Gu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
- (2018) Aurore Perrot et al. BLOOD
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
- (2018) Meletios A. Dimopoulos et al. HAEMATOLOGICA
- High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes
- (2018) Bei Hu et al. LEUKEMIA & LYMPHOMA
- A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses
- (2018) Dean Langan et al. Research Synthesis Methods
- Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
- (2018) Manuela Gambella et al. CANCER
- Minimal residual disease and log‐reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma
- (2018) Giovanni Rossi et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- (2018) Graham H Jackson et al. LANCET ONCOLOGY
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- (2018) L. Rasche et al. LEUKEMIA
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- (2017) Carolina Schinke et al. HAEMATOLOGICA
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
- (2017) J Flores-Montero et al. LEUKEMIA
- Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
- (2017) J Martinez-Lopez et al. LEUKEMIA
- High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
- (2017) J R Mills et al. Blood Cancer Journal
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- (2017) Carolina Schinke et al. HAEMATOLOGICA
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
- (2017) Nikhil C. Munshi et al. JAMA Oncology
- Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
- (2016) O Landgren et al. BONE MARROW TRANSPLANTATION
- Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response
- (2016) Kota Fukumoto et al. LEUKEMIA & LYMPHOMA
- New criteria for response assessment: role of minimal residual disease in multiple myeloma
- (2015) B. Paiva et al. BLOOD
- Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up
- (2015) Heinz Ludwig et al. BRITISH JOURNAL OF HAEMATOLOGY
- Multiple Myeloma, Version 2.2016
- (2015) Kenneth C. Anderson et al. Journal of the National Comprehensive Cancer Network
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Conducting Meta-Analyses inRwith themetaforPackage
- (2015) Wolfgang Viechtbauer Journal of Statistical Software
- GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
- (2014) M.-V. Mateos et al. BLOOD
- The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
- (2014) B. Paiva et al. HAEMATOLOGICA
- Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
- (2014) S Ferrero et al. LEUKEMIA
- Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma
- (2014) R Silvennoinen et al. Blood Cancer Journal
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter
- (2011) Mark Korthals et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
- (2011) B. Paiva et al. BLOOD
- Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma
- (2010) Mervi Putkonen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response
- (2008) Pilar Martínez-Sánchez et al. BRITISH JOURNAL OF HAEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now